{"disease":{"id":"liver-carcinoma","name":"liver carcinoma"},"drugs":{"marketed":[{"drug_id":"durvalumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"atezolizumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"cabometyx","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"Cabometyx","company_name":"Exelixis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2200","mechanism":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis."},{"drug_id":"bevacizumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"lenvatinib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"ramucirumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"regorafenib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stivarga","generic_name":"regorafenib","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Bifunctional epoxide hydrolase 2","drug_class":"Kinase Inhibitor","quality_score":86,"revenue":"400","mechanism":"Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis."},{"drug_id":"tremelimumab","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"sorafenib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexavar","generic_name":"SORAFENIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor [EPC]","quality_score":65,"revenue":"200","mechanism":""},{"drug_id":"cabozantinib","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cometriq","generic_name":"CABOZANTINIB","company_name":"Exelixis Inc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Kinase Inhibitor","quality_score":53,"revenue":null,"mechanism":"Cometriq works by blocking the activity of vascular endothelial growth factor receptor 2, a protein involved in tumor growth and angiogenesis."},{"drug_id":"zirabev","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"nexavar","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nexavar","company_name":"Fujian Medical University","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Cyclin-dependent kinase-like 2, Cyclin-dependent kinase-like 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"tremelimumab-actl","indication_name":"Liver cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT04525833","title":"Liver Disease and Other Systemic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT05355662","title":"Prognosis Analysis of Elderly Donor Liver in Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":11569,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04348838","title":"Prospective Cohort of Patients With Hepatocellular Carcinoma in France","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT06062706","title":"Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":3448,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT00341705","title":"The Second Multicenter Hemophilia Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2565,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04955808","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","phase":"","overall_status":"SUSPENDED","enrollment_count":2400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07298577","title":"Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT03959800","title":"Molecular Basis of Pediatric Liver Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT06179602","title":"Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04414956","title":"Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1418,"lead_sponsor_name":"Korea University","has_results":false},{"nct_id":"NCT03775863","title":"AFP Model and Liver Transplantation.","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Austral University, Argentina","has_results":false},{"nct_id":"NCT07481032","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1034,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT06813508","title":"Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT04785534","title":"Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06331273","title":"Impact of \"No-touch\" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06864195","title":"A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05225207","title":"A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants","phase":"","overall_status":"COMPLETED","enrollment_count":658,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT05971108","title":"Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Manchester University NHS Foundation Trust","has_results":false},{"nct_id":"NCT06331260","title":"Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03533582","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":537,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07224724","title":"Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06418165","title":"Vienna Hypothermic Oxygenated Machine Perfusion Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03981497","title":"Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Francesco De Cobelli","has_results":false},{"nct_id":"NCT05931445","title":"Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Comprehensive Support Project for Oncology Research","has_results":false},{"nct_id":"NCT05866783","title":"Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT07034495","title":"Laparotomy, Laparoscopy, da Vinci System","phase":"","overall_status":"COMPLETED","enrollment_count":486,"lead_sponsor_name":"National Chung Hsing University","has_results":false},{"nct_id":"NCT07418138","title":"Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":484,"lead_sponsor_name":"Hu Liangshuo","has_results":false},{"nct_id":"NCT05321992","title":"Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand","phase":"NA","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT04576572","title":"Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT05863195","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":408,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05517811","title":"Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06342414","title":"An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06958224","title":"Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT05342350","title":"International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy","phase":"","overall_status":"TERMINATED","enrollment_count":360,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06914648","title":"The Dragon PLC Trial (DRAGON-PLC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT06658782","title":"Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06434753","title":"Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT04567615","title":"A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":266,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03164382","title":"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}